Difference between revisions of "Penpulimab (Anniko)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Hodgkin lymphoma" to "Classical Hodgkin lymphoma") |
Warner-admin (talk | contribs) m (Text replacement - "[[Hodgkin lymphoma|" to "[[Classical Hodgkin lymphoma|") |
||
| Line 7: | Line 7: | ||
==History of changes in NMPA indication== | ==History of changes in NMPA indication== | ||
| − | *2021-08-05: Approved for treatment of patients with relapsed or refractory ("r/r") [[Hodgkin lymphoma|classic Hodgkin’s lymphoma ("cHL")]] after at least second-line systemic chemotherapy treatment. | + | *2021-08-05: Approved for treatment of patients with relapsed or refractory ("r/r") [[Classical Hodgkin lymphoma|classic Hodgkin’s lymphoma ("cHL")]] after at least second-line systemic chemotherapy treatment. |
==Also known as== | ==Also known as== | ||
Revision as of 20:54, 9 June 2023
Note: Penpulimab is approved in China, but does not appear to have a brand name at this time.
Mechanism of action
PD-1 inhibitor
Diseases for which it is used
History of changes in NMPA indication
- 2021-08-05: Approved for treatment of patients with relapsed or refractory ("r/r") classic Hodgkin’s lymphoma ("cHL") after at least second-line systemic chemotherapy treatment.
Also known as
- Code name: AK105